Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 8, 2007

Caliper Launches Comprehensive Discovery and Development Services Business

  • Caliper Life Sciences unveiled Caliper Discovery Alliances & Services (CDAS), the services organization born out of the integration of NovaScreen Biosciences an in vitro discovery service provider and Xenogen Biosciences an in vivo discovery service provider.

    “We are excited to now be one of the few providers focused on offering services that span in vitro and in vivo experimentation,” says David Manyak, executive vp of discovery services of Caliper and head of CDAS.

    Caliper acquired NovaScreen in October 2005 and Xenogen in August 2006. The company says that its strategy is to provide its customers with the tools for building an in vitro-in vivo bridge, or an I-I Bridge, to address the growing pressure on the pharmaceutical industry to find new, effective drugs while minimizing the risk of adverse effects of those drugs. "By building the I-I Bridge in the context of a services offering, we are providing scientists a way to explore new approaches to drug discovery with minimal resource commitment," remarks Kevin Hrusovsky, president and CEO of Caliper.

    Caliper Discovery Alliances & Services offers more than 700 in vitro assay types, profiling assays, side effect and ADME-tox panels, and cellular models for immunology, oncology, and other fields, reports Caliper. In vivo offerings include more than 85 pharmacological assays that measure over 400 different parameters, adds the company.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »